` FORA (Forian Inc) vs S&P 500 Comparison - Alpha Spread

FORA
vs
S&P 500

Over the past 12 months, FORA has underperformed S&P 500, delivering a return of +4% compared to the S&P 500's +14% growth.

Stocks Performance
FORA vs S&P 500

Loading
FORA
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
FORA vs S&P 500

Performance Gap Between FORA and GSPC
HIDDEN
Show

Performance By Year
FORA vs S&P 500

Loading
FORA
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Forian Inc vs Peers

S&P 500
FORA
VEEV
PME
2413
DOCS
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Forian Inc
Glance View

Market Cap
66m USD
Industry
Health Care

Forian, Inc. engages in the provision of healthcare information, analytics and technology services. The company is headquartered in Newtown, Pennsylvania and currently employs 138 full-time employees. The company went IPO on 2021-03-03. The firm provides software solutions, data and predictive analytics to optimize the operational, clinical and financial performance of its healthcare, cannabis, and government customers. Its BioTrack vertically integrated point-of-sale, manufacturing, delivery and cultivator software solution is a commercial platform in the cannabis industry, serving dispensaries, cultivators, manufacturers and distributors within 38 states and Puerto Rico. Its Cannalytics software as a service (SaaS)-based analytics solution is a platform that provides clients with a configurable and flexible presentation of business performance. Its real world experience (RWE) solutions are designed to enable the integration otherwise unconnected and disparate data to enable near real-time surveillance of adverse events and to study the clinical economic and social impacts of various therapeutic alternatives, including those derived from cannabinoids and psychedelics.

FORA Intrinsic Value
HIDDEN
Show
Back to Top